Characteristics of Anti-Xa level and Thrombelastography (TEG) in anticoagulant therapy for venous thromboembolism during pregnancy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051002

Enrollment

Unknown

Registered

2021-09-10

Start date

2021-09-11

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism

Interventions

case series:No interventions

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Pregnant women who were diagnosed with VTE following CUS and/or CTPA over 18 and volunteered to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: Exclusion criteria were age less than 18, indication for or current receipt of full-dose anticoagulation,impaired renal function (defined as creatinine clearance <30 mL/min ),platelet count lower than 70 x 10^9/L, severe PE with hemodynamic instability.

Design outcomes

Primary

Measure	Time frame
Anti-Xa level;Thrombelastography;	—

Countries

China

Contacts

Public ContactXu Zhendong

Department of ICU, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine

btxzd123@126.com+86 13817029904

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 21, 2026